Long-term follow-up of the QuantiFERON TB-2G test for active tuberculosis disease

Internal Medicine

Volumn 47, Issue 22, 2008, Pages 1957-1961

  Kobashi, Yoshihiro ^a   Sugiu, Tadaaki ^a   Ohue, Yoshihiro ^a   Mouri, Keiji ^a   Obase, Yasushi ^a   Miyashita, Naoyuki ^a   Oka, Mikio ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

Active tuberculosis (TB); Antituberculosis treatment; Monitoring marker; QuantiFERON TB 2G (QFT 2G)

Indexed keywords

BCG VACCINE; ETHAMBUTOL; GAMMA INTERFERON; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; LUNG TUBERCULOSIS; MALE; MILIARY TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PATIENT MONITORING; REFERENCE VALUE; SPUTUM CULTURE; TREATMENT DURATION; TREATMENT OUTCOME; TUBERCULOSIS; TUBERCULOUS PLEURISY;

ANTITUBERCULAR AGENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERFERON-GAMMA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TIME; TUBERCULIN TEST; TUBERCULOSIS;

EID: 59949088334     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.47.1313     Document Type: Article

References (7)

1. Pai M. Joshi R. Dogra S. et al. Serial testing of health care workers for tuberculosis using interferon-γ assay. Am J Respir Crit Care Med 174: 349-355, 2006.
2. Chee CBE, KhinMar KW, Gan SH, Barkham TMS, Pushparani M, Wang YT. Latent tuberculosis infection treatment and T-cell responses to Mycobacterium tuberculosis-specific antigens. Am J Respir Crit Care Med 175: 282-287, 2007.
3. Mazurek GH, Jereb J, Lobue P, Iademarco MF, Mdetchock B, Vernon A. Division of Tuberculosis Elimination. National Center for HIV, STD, and TB Prevention. Centers for Disease Control and Prevention. Guidelines for using the QuantiFERON-TB Gold test for detecting. Mycobacterium tuberculosis infection. United States. MMWR Recomm Rep 54: 49-55, 2005.
4. Nicol MP, Pienaar D, Wood K. et al. Enzyme-linked immunospot assay responses to early secretory antigenic target 6. culture filtrate protein 10, and purified protein derivative among children with tuberculosis: implications for diagnosis and monitoring of therapy. Clin Infect Dis 40: 1301-1308, 2005.
5. Aiken AM, Hill PC, Fox A, et al. Reversion of ELISPOT test after treatment in Gambian tuberculosis cases. BMC Infect Dis 6: 66, 2006.
6. Kobashi Y, Obase Y, Fukuda M, Yoshida K, Miyashita N, Oka M. Clinical reevaluation of the QuantiFERON TB-2G test as a diagnostic method for differentiating active tuberculosis from nontuberculosis mycobacteriosis. Clin Infect Dis 43: 1540-1546, 2006.
7. Pu M, Joshi R, Dogra S. et al. Persistently elevated T-cell interferon-gamma responses after treatment for latent tuberculosis infection among health care workers in India: a preliminary report. J Occup Med Toxicol 1-7, 2006.